| Product vision |
- Intermittent preventive treatment during pregnancy (IPTp)
- Intermittent preventive treatment of infants (IPTi)
|
| Dosing |
- 3 tablets of 500 mg sulfadoxine - 25 mg pyrimethamine, to be given at the beginning of the 2nd trimester of pregnancy until delivery
|
| Efficacy |
- WHO affirmed the effectiveness of IPTp using SP (IPTp-SP), including in areas with SP resistance
- Estimates indicate that a full course of IPTp-SP decreases the incidence of low birth weight babies by 29%, severe maternal anaemia by 38%, and neonatal mortality by 31%. It is also one of the few health interventions showing reductions in neonatal mortality
|
| Key features |
- Adapted SP packaging to ensure correct use and to improve perception and uptake
|
| Challenges |
- Delivery of IPTp requires a functioning antenatal care platform and access to quality-assured SP
- Improving quality perceptions about SP and expanding access through community health worker channels can increase IPTp coverage
|
| Status |
- Dossier submitted to WHO Prequalification in December 2019; approved in Kenya with further country registration submissions planned
- 250 mg sulphadoxine-12.5 mg pyrimethamine dispersible tablets for use in infants (IPTi) approved by Global Fund Expert Review Panel on 23 February 2022
|
| Next milestone |
- WHO Prequalification anticipated in Q2 2022
|
| MMV Project Director |
|
